Biopolymer Array Quality Control via In Situ Synthesis Feedback
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current peptide arrays for assessing polynucleotide and polypeptide concentrations and expressions have low density and fidelity, making them inadequate for diagnostic assays.
Innovation Solution
Methods and compositions are developed to determine the quality of biopolymer arrays by synthesizing compounds in situ on the array surface, incubating with biological samples, detecting target binding, and comparing average target binding values to a universal average intensity value to assess fidelity and density.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If peptide arrays are used for diagnostic assays, then polynucleotide and polypeptide concentrations and expressions can be assessed, but the arrays have low density and low fidelity which limits their effectiveness
Solution Approach 1:
The patent implements a feedback mechanism where target binding values are measured and compared against expected ranges to identify synthesis step failures. This quality control feedback loop enables correction of fidelity issues while maintaining high density, directly resolving the technical contradiction between measurement precision and quantity of substance.
Solution Approach 2:
The patent performs preliminary quality control assessment by measuring target binding at each synthesis step before final array completion. This preliminary detection of synthesis failures allows for early identification and correction of fidelity issues, enabling the array to achieve both high density and high fidelity simultaneously.
2Quantity of substance
If synthesis steps are performed to create high-density peptide arrays, then array density increases, but synthesis failures reduce array fidelity
Solution Approach 1:
The patent uses feedback from target binding measurements to monitor synthesis quality at each step. By comparing measured binding values against expected ranges, the system identifies synthesis failures and can correct them, maintaining reliability while achieving high density through multiple synthesis steps.
Solution Approach 2:
The patent performs preliminary quality assessment measurements after each synthesis step to detect failures before they propagate through subsequent steps. This preliminary detection enables corrective actions that preserve both the high density achieved through multiple steps and the reliability of the final array.
3Measurement precision
If quality control methods are implemented to improve array fidelity, then measurement accuracy increases, but the complexity of the diagnostic procedure increases
Solution Approach 1:
The patent implements self-service quality control where the array itself provides the measurement data needed for quality assessment through target binding. This self-generated feedback eliminates the need for separate complex quality control procedures, achieving high measurement precision without proportionally increasing procedural complexity.
Solution Approach 2:
The patent uses the same target binding measurement for both quality control and diagnostic purposes. This multi-functional approach allows quality assessment to be integrated into the diagnostic procedure itself, improving measurement precision without adding separate complex quality control steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach allows for effective quality control of biopolymer arrays, ensuring they meet necessary standards for diagnostic assays by identifying failures or successes in synthesis steps, thereby improving assay reliability and accuracy.
Implementation Method 1
detecting target binding on individual compounds on the biopolymer array
Data Source
AI summary
The present application provides arrays for use in immunosignaturing and quality control of such arrays. Also disclosed are peptide arrays and uses thereof for diagnostics, therapeutics and research.